---
title: "Panlong Pharmaceutical 2024 Q3 dividend distribution: 0.5 yuan for every 10 shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227511533.md"
description: "According to the Zhitong Finance APP, Panlong Pharmaceutical announced that the equity distribution plan for the third quarter of 2024 is: based on the existing total share capital of the company after deducting the repurchased shares, a cash dividend of RMB 0.500001 per 10 shares (including tax) will be distributed to all shareholders. The equity distribution registration date is: February 14, 2025, and the ex-dividend date is: February 17, 2025"
datetime: "2025-02-07T10:28:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227511533.md)
  - [en](https://longbridge.com/en/news/227511533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227511533.md)
generator: "portal-rs"
---

# Panlong Pharmaceutical 2024 Q3 dividend distribution: 0.5 yuan for every 10 shares

According to the announcement from Panlong Pharmaceutical (002864.SZ), the equity distribution plan for the third quarter of 2024 is as follows: based on the total share capital of the company after excluding repurchased shares, a cash dividend of RMB 0.500001 per 10 shares (including tax) will be distributed to all shareholders. The equity registration date for this distribution is February 14, 2025, and the ex-dividend date is February 17, 2025

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [15:53 ETFoundations to Freedom Named Primary Partner of Carson Ware for the Winn-Dixie 250 at Daytona International Speedway](https://longbridge.com/en/news/296823183.md)
- [Andritz wins repeat orders from Nanning Sun Paper for China pulp and paper project](https://longbridge.com/en/news/296993005.md)
- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**